Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF β-Smad signal pathway.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
- Publication Information:
Original Publication: San Francisco, CA : Public Library of Science
- Subject Terms:
- Abstract:
Previous studies showed that prostacyclin inhibited fibrosis. However, both receptors of prostacyclin, prostacyclin receptor (IP) and peroxisome proliferator-activated receptor (PPAR), are abundant in cardiac fibroblasts. Here we investigated which receptor was vital in the anti-fibrosis effect of prostacyclin. In addition, the possible mechanism involved in protective effects of prostacyclin against cardiac fibrosis was also studied. We found that beraprost, a prostacyclin analogue, inhibited angiotensin II (Ang II)-induced neonatal rat cardiac fibroblast proliferation in a concentration-dependent and time-dependent manner. Beraprost also suppressed Ang II-induced collagen I mRNA expression and protein synthesis in cardiac fibroblasts. After IP expression was knocked down by siRNA, Ang II-induced proliferation and collagen I synthesis could no longer be rescued by beraprost. However, treating cells with different specific inhibitors of PPAR subtypes prior to beraprost and Ang II stimulation, all of the above attenuating effects of beraprost were still available. Moreover, beraprost significantly blocked transforming growth factor β (TGF β) expression as well as Smad2 phosphorylation and reduced Smad-DNA binding activity. Beraprost also increased phosphorylation of cAMP response element binding protein (CREB) at Ser133 in the nucleus. Co-immunoprecipitation analysis revealed that beraprost increased CREB but decreased Smad2 binding to CREB-binding protein (CBP) in nucleus. In conclusion, beraprost inhibits cardiac fibroblast proliferation by activating IP and suppressing TGF β-Smad signal pathway.
- References:
Trends Pharmacol Sci. 2012 Oct;33(10):559-64. (PMID: 22727878)
J Biol Chem. 2011 Sep 9;286(36):31473-9. (PMID: 21775429)
J Pathol. 2013 Jan;229(2):347-54. (PMID: 23011894)
Cardiovasc Res. 2007 Aug 1;75(3):519-29. (PMID: 17543901)
PLoS One. 2013 Nov 18;8(11):e79215. (PMID: 24260171)
Am J Pathol. 2011 Dec;179(6):2835-44. (PMID: 22015457)
J Cardiovasc Pharmacol. 2009 Jul;54(1):16-24. (PMID: 19487956)
J Hypertens. 2010 Sep;28 Suppl 1:S25-32. (PMID: 20823713)
J Mol Cell Cardiol. 2010 Aug;49(2):176-85. (PMID: 20403362)
Pharmacol Res. 2006 Apr;53(4):359-66. (PMID: 16488624)
Biochem Pharmacol. 2011 Feb 15;81(4):534-43. (PMID: 21146504)
Circulation. 2005 Jul 5;112(1):84-92. (PMID: 15983244)
Am J Respir Cell Mol Biol. 2012 Mar;46(3):372-9. (PMID: 22021335)
Am J Respir Cell Mol Biol. 2013 Jun;48(6):733-41. (PMID: 23418342)
Am J Physiol Cell Physiol. 2009 Aug;297(2):C321-9. (PMID: 19587222)
Circ Res. 2010 Jul 23;107(2):252-62. (PMID: 20522807)
Circ Res. 2009 Aug 28;105(5):471-80. (PMID: 19628794)
Circulation. 2012 Sep 11;126(11):1373-84. (PMID: 22865892)
Circulation. 2001 Oct 30;104(18):2210-5. (PMID: 11684633)
Arterioscler Thromb Vasc Biol. 2008 May;28(5):863-70. (PMID: 18309113)
J Vet Med Sci. 2007 Dec;69(12):1271-6. (PMID: 18176024)
Circ Res. 2008 Apr 25;102(8):986-93. (PMID: 18323528)
Cancer Prev Res (Phila). 2008 Oct;1(5):349-56. (PMID: 19138979)
Hypertension. 1997 Nov;30(5):1047-53. (PMID: 9369254)
Am J Pathol. 2010 May;176(5):2542-9. (PMID: 20348234)
PLoS One. 2012;7(5):e35144. (PMID: 22574112)
PLoS One. 2011 Jan 06;6(1):e15909. (PMID: 21253589)
Reprod Fertil Dev. 2009;21(3):400-7. (PMID: 19261217)
PLoS One. 2012;7(7):e41857. (PMID: 22860019)
Am J Respir Cell Mol Biol. 2012 Aug;47(2):170-7. (PMID: 22403804)
Am J Physiol Renal Physiol. 2009 Oct;297(4):F1109-18. (PMID: 19640904)
Circ Res. 2013 Jan 4;112(1):195-208. (PMID: 23287455)
Am J Physiol Renal Physiol. 2012 Jun 15;302(12):F1616-29. (PMID: 22419696)
Methods Mol Med. 2005;117:273-90. (PMID: 16130232)
Eur J Pharmacol. 2013 Sep 5;715(1-3):196-203. (PMID: 23791613)
J Neurooncol. 2014 Apr;117(2):225-34. (PMID: 24493576)
Nat Rev Cardiol. 2013 Jan;10(1):15-26. (PMID: 23207731)
J Biol Chem. 2013 Aug 2;288(31):22584-95. (PMID: 23775082)
BMC Complement Altern Med. 2013 Jul 23;13:188. (PMID: 23879679)
PLoS One. 2013;8(2):e53819. (PMID: 23457445)
Life Sci. 2011 Nov 7;89(19-20):671-6. (PMID: 21855554)
J Cell Physiol. 2012 Jan;227(1):239-49. (PMID: 21412771)
Cancers (Basel). 2013 Oct 21;5(4):1261-70. (PMID: 24202445)
Cardiovasc Res. 2011 Jul 1;91(1):80-9. (PMID: 21367774)
Hypertension. 2013 Apr;61(4):751-6. (PMID: 23381794)
Neurochem Int. 2013 Oct;63(4):322-30. (PMID: 23811400)
PLoS One. 2013 Jul 16;8(7):e69037. (PMID: 23874858)
Curr Vasc Pharmacol. 2015;13(1):54-63. (PMID: 23628005)
Circ Res. 2007 May 25;100(10):1476-85. (PMID: 17463319)
J Cell Physiol. 2008 Feb;214(2):434-41. (PMID: 17620284)
Mol Cell Biol. 2000 Mar;20(5):1546-52. (PMID: 10669732)
Nature. 1997 Dec 4;390(6659):465-71. (PMID: 9393997)
J Nutr Biochem. 2010 Jul;21(7):580-8. (PMID: 19447019)
J Cardiovasc Transl Res. 2012 Dec;5(6):837-47. (PMID: 22956156)
Circ Res. 2010 Jun 11;106(11):1675-80. (PMID: 20538689)
Mediators Inflamm. 2012;2012:926968. (PMID: 22851816)
FASEB J. 2002 Dec;16(14):1949-51. (PMID: 12368229)
PLoS One. 2013 Sep 02;8(9):e72120. (PMID: 24023727)
PLoS One. 2013 Nov 11;8(11):e78695. (PMID: 24244341)
Biomed Res. 2013;34(5):241-50. (PMID: 24190236)
Am J Physiol Renal Physiol. 2013 Mar 1;304(5):F601-13. (PMID: 23235480)
Br J Pharmacol. 2013 Jun;169(3):590-603. (PMID: 23297769)
FASEB J. 2012 Jun;26(6):2580-91. (PMID: 22415310)
J Recept Signal Transduct Res. 2013 Dec;33(6):349-52. (PMID: 24050824)
- Accession Number:
0 (DNA Primers)
0 (Receptors, Epoprostenol)
0 (Smad Proteins)
0 (Transforming Growth Factor beta)
11128-99-7 (Angiotensin II)
35E3NJJ4O6 (beraprost)
DCR9Z582X0 (Epoprostenol)
- Publication Date:
Date Created: 20140524 Date Completed: 20150120 Latest Revision: 20211021
- Publication Date:
20231215
- Accession Number:
PMC4031177
- Accession Number:
10.1371/journal.pone.0098483
- Accession Number:
24852754
No Comments.